Florent Petitprez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4845746/publications.pdf

Version: 2024-02-01

47	9,254	186209	302012
papers	citations	28 h-index	39 g-index

58	58	58	11045
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Estimating theÂpopulation abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biology, 2016, 17, 218.	3.8	1,980
2	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	13.7	1,421
3	B cells are associated with survival and immunotherapy response in sarcoma. Nature, 2020, 577, 556-560.	13.7	1,158
4	Tertiary lymphoid structures in the era of cancer immunotherapy. Nature Reviews Cancer, 2019, 19, 307-325.	12.8	879
5	Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics, 2019, 35, i436-i445.	1.8	576
6	The clinical role of the TME in solid cancer. British Journal of Cancer, 2019, 120, 45-53.	2.9	380
7	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Frontiers in Immunology, 2020, 11, 784.	2.2	339
8	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 4416-4428.	3.2	252
9	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 58-65.	1.8	219
10	Context-dependent roles of complement in cancer. Nature Reviews Cancer, 2019, 19, 698-715.	12.8	217
11	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity, 2022, 55, 527-541.e5.	6.6	215
12	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nature Reviews Clinical Oncology, 2022, 19, 441-457.	12.5	176
13	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. Cancer Immunology Research, 2019, 7, 1091-1105.	1.6	153
14	Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathyâ€“associated C3 glomerulopathy. Blood, 2017, 129, 1437-1447.	0.6	120
15	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney International, 2017, 92, 1232-1241.	2.6	93
16	B cells and cancer: To B or not to B?. Journal of Experimental Medicine, 2021, 218, .	4.2	91
17	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. Cancer Immunology, Immunotherapy, 2018, 67, 981-988.	2.0	89
18	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2019, 30, 2449-2463.	3.0	81

#	Article	IF	Citations
19	PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. European Urology Focus, 2019, 5, 192-196.	1.6	81
20	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Medicine, 2020, 12, 86.	3.6	63
21	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. Clinical Cancer Research, 2019, 25, 7351-7362.	3.2	61
22	Association of IL-36Î³ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Cancer Immunology, Immunotherapy, 2019, 68, 109-120.	2.0	59
23	Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. , 2020, 8, e001054.		54
24	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. Frontiers in Oncology, 2018, 8, 390.	1.3	46
25	Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. Seminars in Immunology, 2020, 48, 101406.	2.7	44
26	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. Clinical Cancer Research, 2020, 26, 4381-4389.	3.2	44
27	Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. Haematologica, 2019, 104, 2501-2511.	1.7	40
28	Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. OncoImmunology, 2019, 8, e1505174.	2.1	37
29	Revisiting immune escape in colorectal cancer in the era of immunotherapy. British Journal of Cancer, 2019, 120, 815-818.	2.9	30
30	Immune-based identification of cancer patients at high risk of progression. Current Opinion in Immunology, 2018, 51, 97-102.	2.4	29
31	Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 643065.	1.3	26
32	Genetic determinism of spontaneous masculinisation in XX female rainbow trout: new insights using medium throughput genotyping and whole-genome sequencing. Scientific Reports, 2020, 10, 17693.	1.6	13
33	Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy. Kidney International, 2022, 102, 904-916.	2.6	12
34	Probing instructions for expression regulation in gene nucleotide compositions. PLoS Computational Biology, 2018, 14, e1005921.	1.5	11
35	Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen. Scientific Reports, 2019, 9, 13471.	1.6	9
36	DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.. Journal of Clinical Oncology, 2018, 36, 11501-11501.	0.8	7

#	Article	IF	Citations
37	DECONbench: a benchmarking platform dedicated to deconvolution methods for tumor heterogeneity quantification. BMC Bioinformatics, 2021, 22, 473.	1.2	5
38	Abstract CT059: Epigenetic tumor remodelling to improve the efficacy of immune checkpoint blockade: the NIBIT-M4 clinical trial. , 2018, , .		3
39	Immune classification of soft tissue sarcoma predicts clinical outcome. Annals of Oncology, 2019, 30, v689.	0.6	2
40	Abstract 4045: A novel transcriptomic-based immune classification of soft tissue sarcoma (STS) and its association with molecular characteristics, clinical outcome and response to therapy. , 2018, , .		2
41	Immune classification of soft tissue sarcoma and its association with molecular characteristics, and clinical outcome. Annals of Oncology, 2018, 29, vi35.	0.6	1
42	Intratumoral classical complement pathway promotes tumor growth in renal cancer. Molecular Immunology, 2018, 102, 205.	1.0	0
43	From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments. Annals of Oncology, 2019, 30, v811-v812.	0.6	0
44	Abstract PR03: Immune-based classification of soft-tissue sarcoma is associated with clinical outcome and unveils tertiary lymphoid structures as surrogate biomarker for the clinic. , 2019, , .		0
45	Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.. Journal of Clinical Oncology, 2019, 37, 2549-2549.	0.8	0
46	Abstract 2334: Intratumoral classical complement pathway promotes tumor growth in renal cancer. , 2019, , .		0
47	FC 130: Kinetics of Renal Injury After Rhabdomyolysis: Implication of Innate Immune Cells and Complement Activation. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0